Sponsors (3)
The resolution gives federal recognition that can boost research incentives and advocacy for ataxia but does not provide funding or immediate services, creating hope without guaranteed near-term benefits.
Patients with ataxia and their families gain stronger potential for new treatments because the resolution recognizes ataxia as a rare disease eligible for Orphan Drug Act incentives, improving prospects for research and drug development.
Patients with ataxia and their families receive federal recognition of the condition, which increases public awareness and advocacy leverage that can attract research attention and policy support over time.
Patients with ataxia and their families will likely see no immediate improvement in access to treatments or services because the resolution does not allocate funding or require delivery of services.
Patients with ataxia and people needing specialized care may face raised expectations for new treatments and increased demand for limited specialist services that may not be widely available.
Based on analysis of 2 sections of legislative text.
Formally recognizes and summarizes ataxia as a rare neurodegenerative condition, its causes, impacts, and the limited treatment landscape.
Official title: Designating September 25, 2025, as "National Ataxia Awareness Day", and raising awareness of ataxia, ataxia research, and the search for a cure.
Introduced October 9, 2025 by Cindy Hyde-Smith · Last progress October 9, 2025
Declares facts about ataxia, describing it as a clinical sign of brain degeneration or dysfunction that impairs coordination, precision, and timing of movement. The resolution notes that ataxia can affect people of all ages (including children), covers inherited and noninherited causes, describes the rare-disease status of inherited ataxias under the Orphan Drug Act, and recognizes the physical, psychological, and financial challenges patients and families face as well as the limited treatments and ongoing research.